Steve holds a PhD in Biochemistry from the Faculty of Medicine at the University of Toronto, Canada. He worked as a medical scientist for 18 years, within both industry and academia, where his research focused on the discovery of new medicines to treat inflammatory disorders and infectious diseases. Steve recently stepped away from the lab and into science communications, where he’s helping make medical science information more accessible for everyone.
When used as a first-line therapy to treat newly diagnosed women with advanced ovarian cancer who previously responded to platinum-based chemotherapy, Lynparza (olaparib) prolonged the time they lived without showing signs ... Read more
The addition of Tecentriq (atezolizumab) to first-line treatment with Avastin (bevacizumab) and chemotherapy does not significantly extend survival without disease worsening in people with newly-diagnosed advanced ovarian cancer, a ... Read more
Disrupting genes essential for the cellular recycling process known as autophagy increases the frequency of mutations during cell division and promotes the formation of ovarian cancer tumors, a study ... Read more
A combination of two checkpoint inhibitor therapies, magrolimab (Hu5F9-G4) and Bavencio (avelumab), has an acceptable safety profile, is well-tolerated, and stabilizes disease in more than half of heavily-treated ovarian ... Read more
Using standard platinum-based chemotherapy is often associated with the formation of unfavorable treatment-resistant cancer stem cells, which may ultimately contribute to cancer progression — but inhibiting an enzyme called ... Read more
A second surgery followed by chemotherapy is no better than chemotherapy alone at extending the lives of women with platinum-sensitive ovarian cancer who experienced disease recurrence after a first ... Read more
The search for a cure for ovarian cancer has been given a boost by a $5 million gift that will support the clinical research of David S. Alberts, MD, ... Read more